Orthofix, Stryker Preparing To Capitalize On Growing Bone Graft Market
This article was originally published in The Gray Sheet
Orthofix is looking to benefit from a growing bone graft market as development and marketing partner Stryker expands indications for Orthofix' BoneSource bone substitute material.
You may also be interested in...
Damages from company's successful breach of contract suit against Biomet's EBI subsidiary remain at $64 mil. following the U.S. Supreme Court's denial of Orthofix' petition to review a Third Circuit U.S. Court of Appeals decision that reduced punitive damages from $50 mil. to $1 mil. (1"The Gray Sheet" July 5, In Brief), firm announces Jan. 10. The $64 mil. total includes approximately $49 mil. in compensatory damages and $14.3 mil. in pre- and post-judgement interest. Orthofix expects to net approximately $40 mil. after legal fees and previously announced expenses
Thirteen-center U.S. safety and efficacy clinical trial of the firm's Cervical-Stim non-invasive bone growth stimulator is set to begin following investigational device exemption approval from FDA Sept. 27. The study will evaluate the device for increasing cervical fusion rates for high-risk patients who have a failure rate of up to 50% either from smoking or multi-level fusions, the firm says
Completes acquisition of Pfizer's Howmedica orthopedic division for $1.65 bil. in cash, the firms report Dec. 4. The deal was first announced in August ("The Gray Sheet" Aug. 17, p. 3)